ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Mortality Trends in Risk Conditions and Invasive Mycotic Disease in the United States, 1999-2018.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 61 citations in OpenAlex.
- Evaluating the impact of immunization with the "pan-fungal" vaccine, NXT-2, on the gut mycobiome and microbiome in non-human primates (NHPs).Microbiology spectrum · 2026Article
- Identification of Invasive Aspergillosis in Electronic Health Records.Open forum infectious diseases · 2026Article
- Novel infection byInfection and immunity · 2026Article
- Chitosan nanoparticles loaded with ribavirin, carboplatin, and thyme oil downregulate SNQ2, ERG11, CDR1, and MDR1 in Candida strains.Scientific reports · 2025Article
- Aetiologic diagnosis of thoracic granulomatous diseases: a retrospective multicentre study in South-Central China.BMJ open · 2025Observational
- Active and Passive Immunization of Pan-Fungal Vaccine NXT-2 Reduces Morbidity and Mortality in an Immunosuppressed Murine Model ofVaccines · 2025Article
- Experimental Pneumocystis infection in dexamethasone immunosuppressed macaques.Medical mycology · 2025Article
- Azole drugs have differential efficacy in varied models of immunosuppression in larval zebrafish hosts.Future microbiology · 2025Article
- Predictive nomogram for early detection of invasive fungal disease deterioration --- a 10-year retrospective cohort study.BMC infectious diseases · 2025Article
- Epidemiology, clinical characteristics, and outcome in candidemia: a retrospective five-year analysis from two tertiary general hospitals.BMC infectious diseases · 2025Observational
- Anticancer drugs targeting topoisomerase II for antifungal treatment.Scientific reports · 2025Article
- Article
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
- High prevalence of azole resistance among environmentalFrontiers in microbiology · 2025Article
- Opportunistic pathogens and polycocktail drugs fuel dynamic public health threats during the opioid crisis.PloS one · 2025Article
- Targeting Candida albicans O-acetyl-L-homoserine sulfhydrylase (Met15p) in antifungal treatment.Scientific reports · 2024Article
- Unveiling Drimenol: A Phytochemical with Multifaceted Bioactivities.Plants (Basel, Switzerland) · 2024Review
- Fungal melanin suppresses airway epithelial chemokine secretion through blockade of calcium fluxing.Nature communications · 2024Article
- Dynamics and prognostic value of plasma cell-free DNA PCR in patients with invasive aspergillosis and mucormycosis.Journal of clinical microbiology · 2024Article
- Advanced genetic techniques in fungal pathogen research.mSphere · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundInvasive fungal infections in the United States are chronically underdiagnosed and a lack of coordinated surveillance makes the true burden of disease difficult to determine. The purpose of this analysis was to capture mortality-associated burden of risk conditions and fungal infections.
methodsWe analyzed data from the National Vital Statistics System from 1999 through 2018 to estimate the mortality attributed to risk conditions and related fungal disease.
resultsThe number of risk conditions associated with fungal disease is steadily rising in the United States, with 1 047 422 diagnoses at time of death in 2018. While fungal disease decreased substantially from 1999 to 2010, primarily due to the control of human immunodeficiency virus (HIV) infection, the number of deaths with fungal diagnosis has increased in the non-HIV cohort, with significant increases in patients with diabetes, cancer, immunosuppressive disorders, or sepsis.
conclusionsThe landscape of individuals at risk for serious fungal diseases is changing, with a continued decline in HIV-associated incidence but increased diagnoses in patients with cancer, sepsis, immunosuppressive disorders, and influenza. Additionally, there is an overall increase in the number of fungal infections in recent years, indicating a failure to control fungal disease mortality in these new immunocompromised cohorts. Improvement in the prevention and management of fungal diseases is needed to control morbidity and mortality in the rising number of immunocompromised and at-risk patients in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.